The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Blood Based Biomarkers Market Grow Between 2026 And 2030?
The blood based biomarkers market size has seen rapid growth in recent years. This market is anticipated to expand from $25.83 billion in 2025 to $28.94 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.0%. The increase observed in the past period can be linked to advances in molecular diagnostics, the introduction of cancer screening programs, various biomarker validation studies, improvements in hospital diagnostic infrastructure, and growth in research funding.
The blood based biomarkers market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $45.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.0%. Factors contributing to this growth during the forecast period include the expanding use of liquid biopsy, advancements in AI-powered biomarker analytics, the increasing need for chronic disease monitoring, the uptake of personalized medicine, and the proliferation of point-of-care testing. Key trends identified for the forecast period encompass the increasing acceptance of non-invasive diagnostics, the broadening of precision oncology applications, enhanced utilization in early disease detection, a growing requirement for personalized treatment monitoring, and their integration with clinical decision support systems.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp
What Factors Are Contributing To The Growth Of The Blood Based Biomarkers Market?
An increasing incidence of cardiovascular ailments is anticipated to drive the expansion of the blood-based biomarkers market in the future. These diseases encompass various conditions impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The surge in cardiovascular diseases is primarily attributable to escalating risk factors, including inadequate dietary habits and higher obesity prevalence. Blood-based biomarkers assist in the diagnosis and monitoring of cardiovascular conditions by offering valuable information on disease advancement, risk evaluation, and effectiveness of treatment through detectable compounds present in the bloodstream. For example, the National Center for Biotechnology Information, a US-based government agency, shared findings from a global health research initiative in September 2024. This initiative projected a 90% increase in cardiovascular disease prevalence from 2025 to 2050, with fatalities due to these diseases predicted to hit 35.6 million by 2050. Consequently, the rising occurrence of cardiovascular diseases is fueling the development and adoption of blood-based biomarkers.
Which Segment Classifications Are Used In The Blood Based Biomarkers Market Segment Analysis?
The blood based biomarkers market covered in this report is segmented –
1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies
3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications
4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users
Subsegments:
1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions
2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins
3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels
4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells
5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity
What Trends Are Affecting The Growth Of The Blood Based Biomarkers Market?
Leading companies within the blood-based biomarkers market are concentrating on technological improvements, such as highly accurate blood biomarker tests, to support physicians in diagnosing Alzheimer’s disease. A high-accuracy blood biomarker test functions as a diagnostic instrument that utilizes specific biomarkers present in the blood to identify diseases or monitor health conditions with a high degree of precision and reliability. For example, in October 2023, Quanterix, a US-based life sciences company, launched LucentAD p-Tau 217, a high-accuracy blood biomarker test designed to assist physicians in diagnosing Alzheimer’s disease (AD) in adults experiencing cognitive impairment. This test measures phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker strongly associated with AD pathology, particularly the accumulation of amyloid in the brain. The LucentAD p-Tau 217 test achieves over 90% accuracy, satisfying rigorous diagnostic criteria, and is intended for use in conjunction with other diagnostic tools rather than as a sole test.
Which Firms Are Contributing To The Blood Based Biomarkers Market Ecosystem?
Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG
Get The Full Blood Based Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report
Which Region Dominates The Blood Based Biomarkers Market By Market Share?
North America was the largest region in the blood-based biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Blood Based Biomarkers Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report
Browse Through More Reports Similar to the Global Blood Based Biomarkers Market 2026, By The Business Research Company
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Cancer Biomarker Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model